Cicas IP LLC v. Stryker Corporation: Surgical Navigation Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Cicas IP LLC v. Stryker Corporation |
| Case Number | 2:23-cv-00295 (E.D. Tex.) |
| Court | U.S. District Court for the Eastern District of Texas |
| Duration | June 2023 – March 2024 9 months |
| Outcome | Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Stryker’s endoscopic targeting and surgical navigation systems |
Case Overview
The Parties
⚖️ Plaintiff
A non-practicing entity (NPE) asserting patent rights in the medical imaging and surgical navigation technology domain.
🛡️ Defendant
A Fortune 500 global medical device company. Co-defendant Scopis GmbH specializes in augmented reality surgical navigation.
The Patent at Issue
This case involved U.S. Patent No. 6,850,794 B2, covering an endoscopic targeting method and system. This technology enables precise instrument navigation during minimally invasive surgical procedures using endoscopic imaging guidance.
- • US 6,850,794 B2 — Endoscopic targeting method and system (Application No. US09/957477)
Designing a surgical navigation product?
Check if your medical device design might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
On March 21, 2024, the court accepted the parties’ Joint Stipulation of Dismissal, ordering all claims and causes of action dismissed with prejudice. No damages figure was publicly disclosed, and no injunctive relief was granted. This dismissal “with prejudice” means Cicas IP cannot reassert these specific claims against these defendants in future litigation.
Key Legal Issues
Because the matter resolved before any substantive rulings on claim construction, validity, or infringement, there is no public judicial analysis of how the ‘794 patent claims read on Stryker’s accused endoscopic targeting systems. The joint nature of the dismissal stipulation, combined with the “with prejudice” designation and each-party-bears-own-fees structure, is a signature pattern in confidential patent license settlements in the Eastern District of Texas.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in surgical navigation design. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this medical device technology space
- See which companies are most active in surgical navigation patents
- Understand patent claim patterns in endoscopic targeting
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical device technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Endoscopic targeting methods
1 Patent Asserted
But from a broader patent family
Procedural Significance
Illustrates early-stage resolution tactics
✅ Key Takeaways
Dismissal with prejudice following joint stipulation is a strong indicator of confidential licensing resolution — not necessarily plaintiff or defendant “victory.”
Search related case law →The Eastern District of Texas continues to be a high-activity venue for medical device NPE assertions, often leading to rapid pre-trial resolutions.
Explore precedents →Frequently Asked Questions
U.S. Patent No. 6,850,794 B2 (application no. US09/957477), covering an endoscopic targeting method and system, was the sole patent asserted in this case.
The parties filed a Joint Stipulation of Dismissal representing the matter had been resolved, which the court accepted. “With prejudice” means the claims cannot be re-filed against these defendants. No public explanation of the resolution terms was provided.
It reinforces that legacy endoscopic and surgical navigation patents remain viable assertion vehicles against modern medical device companies, and that pre-trial resolutions are common in this space — particularly in the Eastern District of Texas.
Companies in the medical device and surgical navigation space can protect themselves by conducting early and comprehensive Freedom-to-Operate (FTO) analyses, especially for technologies with long development cycles. Thorough IP due diligence during M&A, proactive patent landscaping, and strategic patent filing are also crucial. PatSnap Eureka’s tools help identify potentially blocking patents and navigate complex IP landscapes.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Patent and Trademark Office — U.S. Patent No. 6,850,794 B2
- PACER – Eastern District of Texas Case No. 2:23-cv-00295
- U.S. District Court for the Eastern District of Texas Local Patent Rules
- PatSnap — IP Intelligence Solutions for Medical Device Companies
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.